Estrella Immunopharma (Estrella Immunopharma) Short-Term Debt : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Estrella Immunopharma Short-Term Debt?

Estrella Immunopharma's Short-Term Debt for the quarter that ended in Mar. 2024 was $0.00 Mil.

Estrella Immunopharma's quarterly Short-Term Debt declined from Sep. 2023 ($0.30 Mil) to Dec. 2023 ($0.00 Mil) but then stayed the same from Dec. 2023 ($0.00 Mil) to Mar. 2024 ($0.00 Mil).

Estrella Immunopharma Short-Term Debt Historical Data

The historical data trend for Estrella Immunopharma's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Estrella Immunopharma Short-Term Debt Chart

Estrella Immunopharma Annual Data

Trend

Jun21

Short-Term Debt

Estrella Immunopharma Quarterly Data
	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Short-Term Debt	Get a 7-Day Free Trial					-	-	0.30	-	-

Estrella Immunopharma Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Estrella Immunopharma Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Estrella Immunopharma's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Estrella Immunopharma (Estrella Immunopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Estrella Immunopharma Inc (NAS:ESLA) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

5858 Horton Street, Suite 170, Emeryville, CA, USA, 94608

Website

https://www.estrellabio.com

Estrella Immunopharma Inc is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer.

Estrella Immunopharma (Estrella Immunopharma) Headlines

No Headlines